Could Adamas Pharmaceuticals Inc (ADMS) Lose Strenght? The Stock Increases A Lot Today

September 17, 2017 - By Stephen Andrade

The stock of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) is a huge mover today! The stock increased 4.82% or $0.99 on September 15, reaching $21.53. About 1.18M shares traded. Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has declined 0.40% since September 17, 2016 and is downtrending. It has underperformed by 17.10% the S&P500.
The move comes after 7 months positive chart setup for the $484.73M company. It was reported on Sep, 17 by Barchart.com. We have $22.61 PT which if reached, will make NASDAQ:ADMS worth $24.24M more.

Wall Street await Adamas Pharmaceuticals Inc (NASDAQ:ADMS) to release earnings on November, 2. Analysts forecast earnings per share of $-1.06, down exactly $0.40 or 60.61 % from 2014’s $-0.66 EPS. After posting $-0.93 EPS for the previous quarter, Adamas Pharmaceuticals Inc’s analysts now forecast 13.98 % negative EPS growth.

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) Ratings Coverage

Among 8 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 7 have Buy rating, 1 Sell and 0 Hold. Therefore 88% are positive. Adamas Pharmaceuticals had 20 analyst reports since August 7, 2015 according to SRatingsIntel. Mizuho maintained the shares of ADMS in report on Thursday, May 12 with “Neutral” rating. As per Thursday, September 8, the company rating was maintained by Mizuho. The firm has “Buy” rating by Noble Financial given on Friday, June 17. The stock of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has “Buy” rating given on Thursday, June 16 by Mizuho. Mizuho maintained Adamas Pharmaceuticals Inc (NASDAQ:ADMS) rating on Tuesday, June 6. Mizuho has “Buy” rating and $2600 target. The stock has “Sell” rating by TheStreet on Friday, October 16. The company was initiated on Friday, April 1 by JMP Securities. The rating was maintained by Mizuho on Thursday, April 28 with “Neutral”. The stock of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has “Outperform” rating given on Tuesday, January 19 by Cowen & Co. On Wednesday, August 9 the stock rating was maintained by Cowen & Co with “Buy”.

More notable recent Adamas Pharmaceuticals Inc (NASDAQ:ADMS) news were published by: Marketwatch.com which released: “Adamas Pharma says its new Parkinson’s drug isn’t just a more expensive, long …” on August 29, 2017, also Marketwatch.com with their article: “Adamas Pharma shares soar on Parkinson’s dyskinesia drug approval” published on August 24, 2017, Marketwatch.com published: “Adamas Pharma stock surges 7% after negative FDA decision for rival Acorda’s …” on August 29, 2017. More interesting news about Adamas Pharmaceuticals Inc (NASDAQ:ADMS) were released by: Nasdaq.com and their article: “Adamas to Host Investor and Analyst Meeting on September 18, 2017” published on September 13, 2017 as well as Seekingalpha.com‘s news article titled: “Adamas Prepares For Parkinson’s Launch” with publication date: September 14, 2017.

Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The company has market cap of $484.73 million. The Firm is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It currently has negative earnings. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.